The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures

被引:4
作者
Horikawa, Akira [1 ]
Miyakoshi, Naohisa [2 ]
Hongo, Michio [2 ]
Kasukawa, Yuji [2 ]
Shimada, Yoichi [2 ]
Kodama, Hiroyuki [3 ]
Sano, Akihisa [1 ]
机构
[1] Shizuoka Tokusyukai Hosp, 1-11 Surugaku Simokawahara Minami, Shizuoka 4210117, Japan
[2] Akita Univ, Dept Orthoped Surg, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan
[3] South Akita Orthoped Clin, 96-2 Kaidousita, Syowa Ookubo, Katagami 0181401, Japan
关键词
POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; RISK; BISPHOSPHONATES; EFFICACY; PREVENTION; DENOSUMAB; TRIAL; TERIPARATIDE; IBANDRONATE;
D O I
10.1155/2021/5517247
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
We analyzed the data about the preferences of medication and incidence of fractures between osteoporosis patients from 2012 to 2016. Our results suggested that the number of patients treated with intravenous and subcutaneous injections increased and the incidence of fracture was lower in intravenous and subcutaneous injections than oral medications. Objective. This study focused on the trends in antiosteoporosis drug preferences and compared the incidence of fractures between patients treated orally and those who were exposed to an awareness campaign and assigned to intravenous/subcutaneous treatment. Methods. Our hospital registry included 1,716 osteoporotic women who were over 65 years of age without preexisting vertebral and nonvertebral fractures over 1 year before this study, with bone mineral density (BMD) < -2.5 standard deviation (SD) and fracture assessment tool (FRAX) score > 20%, who were given 1,337 oral and 379 intravenous/subcutaneous prescriptions to treat their osteoporosis. Self-administered surveys (2012, 2013, 2014, 2015, and 2016) collected data on trends of preferences among nine drugs and fracture prevention using relative risk reduction (RRR). Results. The number of patients taking oral prescriptions decreased gradually from 2012 to 2016, while the number of patients treated with intravenous and subcutaneous injections increased. The incidence of fracture was lower in patients receiving intravenous and subcutaneous injections than in patients taking oral medications. Conclusion. These findings indicate a decrease in oral prescriptions for osteoporosis treatment and that treatment for osteoporosis using intravenous or subcutaneous injections of antiosteoporosis drugs is more effective for preventing fractures.
引用
收藏
页数:7
相关论文
共 32 条
[11]  
Eric S.O., 2010, J BONE MINER RES, V25, P2239
[12]  
Genant HK, 1996, J BONE MINER RES, V11, P984
[13]   GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates [J].
Hadji, P. ;
Claus, V. ;
Ziller, V. ;
Intorcia, M. ;
Kostev, K. ;
Steinle, T. .
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) :223-231
[14]   Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment [J].
Hiligsmann, Mickael ;
Dellaert, Benedict G. ;
Dirksen, Carmen D. ;
van der Weijden, Trudy ;
Goemaere, Stefan ;
Reginster, Jean-Yves ;
Watson, Verity ;
Boonen, Annelies .
ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
[15]   The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women [J].
Hopkins, Robert B. ;
Goeree, Ron ;
Pullenayegum, Eleanor ;
Adachi, Jonathan D. ;
Papaioannou, Alexandra ;
Xie, Feng ;
Thabane, Lehana .
BMC MUSCULOSKELETAL DISORDERS, 2011, 12
[16]   The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis [J].
Hwang, Jawl-Shan ;
Chin, Lin-Show ;
Chen, Jung-Fu ;
Yang, Tzay-Shing ;
Chen, Po-Quang ;
Tsai, Keh-Sung ;
Leung, Ping Chung .
JOURNAL OF BONE AND MINERAL METABOLISM, 2011, 29 (03) :328-333
[17]   ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS - SYNOPSIS OF A WHO REPORT [J].
KANIS, JA ;
ALEXEEVA, L ;
BONJOUR, JP ;
BURKHARDT, P ;
CHRISTIANSEN, C ;
COOPER, C ;
DELMAS, P ;
JOHNELL, O ;
JOHNSTON, C ;
KANIS, JA ;
KHALTAEV, N ;
LIPS, P ;
MAZZUOLI, G ;
MELTON, LJ ;
MEUNIER, P ;
SEEMAN, E ;
STEPAN, J ;
TOSTESON, A .
OSTEOPOROSIS INTERNATIONAL, 1994, 4 (06) :368-381
[18]  
Kenneth W.L., 2007, NEW ENGL J MED, V357, P1799
[19]  
Migliore A, 2013, EUR REV MED PHARMACO, V17, P658
[20]   Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study) [J].
Nakamura, T. ;
Fukunaga, M. ;
Nakano, T. ;
Kishimoto, H. ;
Ito, M. ;
Hagino, H. ;
Sone, T. ;
Taguchi, A. ;
Tanaka, S. ;
Ohashi, M. ;
Ota, Y. ;
Shiraki, M. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (01) :389-398